arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Processa Pharmaceuticals, Inc.

PCSA
$2.61 ▲ +0.30 (+13.23%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

Processa Pharmaceuticals, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $6.8M
Dividend Yield
Revenue Growth None
Op. Margin
ROIC -103.6%
FCF / Share $-1.37
Trailing P/E
Price / Book 2.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-3.38M
↓ -19.1%
FCF / Share Free cash flow per share
$-1.37
↓ -377.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
1
Financial Health
2
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 56 quarters